Skip to content
10-K

Annual Report

MEREO BIOPHARMA GROUP PLC MREO

0000950170-25-044787

← back to feed
Filed
Mar 26, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 25, 2025 795M sh
Stock Issued FY 2024 · Jun 30, 2024 12.53M sh
Shares Diluted FY 2024 · Dec 31, 2023 659.45M sh
Operating Cash Flow FY 2024 · Dec 31, 2023 −$21.13M
Cash And Equivalents FY 2024 · Dec 31, 2023 $57.42M
Current Liabilities FY 2024 · Dec 31, 2023 $9.49M
Total Liabilities FY 2024 · Dec 31, 2023 $15.96M
Current Assets FY 2024 · Dec 31, 2023 $63.76M
Total Assets FY 2024 · Dec 31, 2023 $66.5M
Eps Diluted FY 2024 · Dec 31, 2023 −$0.04
Eps Basic FY 2024 · Dec 31, 2023 −$0.04
Sga Expense FY 2024 · Dec 31, 2023 $18.42M
Rd Expense FY 2024 · Dec 31, 2023 $17.42M
Net Income FY 2024 · Dec 31, 2023 −$29.47M
Operating Income FY 2024 · Dec 31, 2023 −$28.42M
Revenue FY 2024 · Dec 31, 2023 $10M
Stockholders Equity FY 2024 · Dec 31, 2022 $51.4M